NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
We’re looking forward to #WORLDSymposium 2026, where the global lysosomal disease community comes together to share science and progress.
#NSPharma is proud to present and engage with everyone working to advance care for #RareDiseases.
Register here: https://ow.ly/JFCf50Y3CxG https://x.com/NSPharmaInc/status/2015802240548708807/photo/1
Please welcome Shaun Flaherty to #NSPharma as Area Business Director!
With 15+ years in sales leadership, account management and reimbursement across oncology, urology and cardiology, Shaun brings deep experience to the team. We're excited to have you on board!
#NewHire https://x.com/NSPharmaInc/status/2014715146149491166/photo/1
#NSPharma is proud to sponsor #ClinicalTrials for brogidirsen (NS-089/NCNP-02), which has 3.5-year efficacy and safety data presented at the 2025 World Muscle Society Congress.
Learn more about #DMD clinical trials: https://ow.ly/xkFf50Y0xOf https://x.com/NSPharmaInc/status/2013990329590992938/photo/1
NSPharma is proud to sponsor #PPMD Understanding Dystrophinopathy Care event in New York, Jan 21–23.
This gathering brings us together to connect, and share our insights and experiences in #Duchenne and #Becker care.
Learn more & register: https://donate.parentprojectmd.org/event/understanding-dystrophinopathy-care-in-an-evolving-environment/e718213
#RareDisease https://x.com/NSPharmaInc/status/2013265639020933504/photo/1
#WelcomeToTheTeam Jared Sternberg as HCP Marketing Senior Manager!
With 20+ years of experience across CNS, neurology, endocrinology and rare diseases, Jared brings deep launch and strategy expertise from Amneal, Allergan, and more. #NSPharma is excited to have you!
#NewHire https://x.com/NSPharmaInc/status/2012178431190958491/photo/1
We’re excited to join families, caregivers, clinicians and researchers for a day of learning and connection at the latest #CureDuchenne Workshop!
📅 Jan 17, 8 AM–4 PM
📍 Miami Marriott Dadeland.
Register here: https://ow.ly/5Wr950XWByg
#RareDisease #NSPharma https://x.com/NSPharmaInc/status/2011453701387411636/photo/1
We’re continuing to grow our team at #NSPharma. We’re #NowHiring a Senior Director, Market Access, a key role for an experienced leader passionate about improving access to therapies for people living with #RareDiseases.
Learn more and apply: https://ow.ly/E25F50XVpZ6 https://x.com/NSPharmaInc/status/2010728774531256724/photo/1
